Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure

Abstract Aims In this prospective, placebo‐controlled, double‐blind, exploratory study, we examined early and more delayed effects of empagliflozin treatment on haemodynamic parameters (primary endpoint: cardiac output) and kidney function including parameters of acute kidney injury (AKI) in patient...

Full description

Bibliographic Details
Main Authors: Kirsten Thiele, Matthias Rau, Niels‐Ulrik Korbinian Hartmann, Marcus Möller, Julia Möllmann, Joachim Jankowski, András P. Keszei, Michael Böhm, Jürgen Floege, Nikolaus Marx, Michael Lehrke
Format: Article
Language:English
Published: Wiley 2022-08-01
Series:ESC Heart Failure
Subjects:
SGLT2 inhibitors
Empagliflozin
Acute decompensated heart failure
Acute kidney injury
Haemodynamic parameters
Online Access:https://doi.org/10.1002/ehf2.13955

Internet

https://doi.org/10.1002/ehf2.13955

Similar Items